[go: up one dir, main page]

ZA200705231B - Use of oxycodone for treating visceral pain - Google Patents

Use of oxycodone for treating visceral pain

Info

Publication number
ZA200705231B
ZA200705231B ZA200705231A ZA200705231A ZA200705231B ZA 200705231 B ZA200705231 B ZA 200705231B ZA 200705231 A ZA200705231 A ZA 200705231A ZA 200705231 A ZA200705231 A ZA 200705231A ZA 200705231 B ZA200705231 B ZA 200705231B
Authority
ZA
South Africa
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
ZA200705231A
Other languages
English (en)
Inventor
Drewes Asbjorn Mohr
Nielsen Lars Arendt
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200705231(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of ZA200705231B publication Critical patent/ZA200705231B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200705231A 2005-01-18 2007-07-02 Use of oxycodone for treating visceral pain ZA200705231B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
ZA200705231B true ZA200705231B (en) 2008-06-25

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705231A ZA200705231B (en) 2005-01-18 2007-07-02 Use of oxycodone for treating visceral pain

Country Status (31)

Country Link
US (2) US20080200493A1 (pl)
EP (1) EP1838318B1 (pl)
JP (1) JP5049139B2 (pl)
KR (10) KR20230170811A (pl)
CN (1) CN101106996B (pl)
AP (1) AP2249A (pl)
AR (1) AR052880A1 (pl)
AT (2) ATE446092T1 (pl)
AU (1) AU2006207498B2 (pl)
BR (1) BRPI0606247A2 (pl)
CA (1) CA2595043C (pl)
CY (1) CY1109660T1 (pl)
DE (2) DE602006009899D1 (pl)
DK (2) DK1838318T3 (pl)
EA (1) EA013544B1 (pl)
ES (1) ES2333901T3 (pl)
HR (1) HRP20090679T1 (pl)
IL (1) IL184530A (pl)
ME (1) ME01066B (pl)
MX (1) MX2007007207A (pl)
MY (1) MY144471A (pl)
NO (1) NO338968B1 (pl)
NZ (1) NZ555852A (pl)
PL (1) PL1838318T3 (pl)
PT (1) PT1838318E (pl)
RS (1) RS51069B (pl)
SI (1) SI1838318T1 (pl)
TW (1) TWI432196B (pl)
UA (1) UA85471C2 (pl)
WO (1) WO2006077212A1 (pl)
ZA (1) ZA200705231B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CA2771186C (en) * 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
RS58621B1 (sr) 2011-05-20 2019-05-31 Alderbio Holdings Llc Anti-cgrp kompozicije i njihova upotreba
JP6189832B2 (ja) 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー 慢性および急性の下痢を治療または予防するための抗ｃｇｒｐ若しくは抗ｃｇｒｐ−ｒの抗体または抗体断片の使用
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
FI3515937T3 (fi) 2016-09-23 2026-02-11 Teva Pharmaceuticals Int Gmbh Refraktaarisen migreenin hoito
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
PH12021551478A1 (en) 2019-01-08 2022-05-02 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0921802A4 (en) * 1996-03-25 2002-05-08 Lilly Co Eli METHODS FOR TREATING PAIN
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CN101106996B (zh) 2013-10-23
UA85471C2 (ru) 2009-01-26
AP2007004057A0 (en) 2007-08-31
TWI432196B (zh) 2014-04-01
KR20120089710A (ko) 2012-08-13
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
KR20140091782A (ko) 2014-07-22
DK200700207U3 (da) 2007-09-28
CA2595043A1 (en) 2006-07-27
CA2595043C (en) 2013-11-19
NZ555852A (en) 2010-01-29
ME01066B (me) 2012-10-20
HK1107933A1 (en) 2008-04-25
TW200637554A (en) 2006-11-01
BRPI0606247A2 (pt) 2009-06-09
KR20230170811A (ko) 2023-12-19
ATE446092T1 (de) 2009-11-15
DK1838318T3 (da) 2010-01-04
JP2008526927A (ja) 2008-07-24
AR052880A1 (es) 2007-04-11
CY1109660T1 (el) 2014-08-13
SI1838318T1 (sl) 2010-02-26
KR20190135557A (ko) 2019-12-06
AP2249A (en) 2011-07-18
DE202006019887U1 (de) 2007-07-26
EA200701541A1 (ru) 2008-02-28
AU2006207498B2 (en) 2009-11-19
EA013544B1 (ru) 2010-06-30
CN101106996A (zh) 2008-01-16
ES2333901T3 (es) 2010-03-02
KR20080106991A (ko) 2008-12-09
AU2006207498A1 (en) 2006-07-27
JP5049139B2 (ja) 2012-10-17
DK200700207U1 (da) 2007-08-24
NO338968B1 (no) 2016-11-07
US20150190393A1 (en) 2015-07-09
IL184530A0 (en) 2007-10-31
PL1838318T3 (pl) 2010-03-31
US20080200493A1 (en) 2008-08-21
DE602006009899D1 (de) 2009-12-03
EP1838318A1 (en) 2007-10-03
NO20074174L (no) 2007-10-17
HRP20090679T1 (hr) 2010-01-31
IL184530A (en) 2015-01-29
US9271974B2 (en) 2016-03-01
MY144471A (en) 2011-09-30
PT1838318E (pt) 2009-12-15
RS51069B (sr) 2010-10-31
AT9895U1 (de) 2008-05-15
KR20210131450A (ko) 2021-11-02
KR20070100368A (ko) 2007-10-10
KR20220165797A (ko) 2022-12-15
KR20200128451A (ko) 2020-11-12
WO2006077212A1 (en) 2006-07-27
EP1838318B1 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
IL184530A0 (en) Use of oxycodone for treating visceral pain
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
IL248204A0 (en) Combined treatment of tumors expressing 38cd
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL188430A0 (en) Treatment of tumors
IL193460A0 (en) Compounds and methods for treatment of stroke
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
IL201422A0 (en) Therapeutic agents useful for treating pain
GB0404656D0 (en) Treatment of spinal conditions
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
ZA200904478B (en) Novel therapeutic use for treating leukaemia
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
GB0610868D0 (en) Treatment of pain
EP1813271A4 (en) PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
GB0408521D0 (en) Treatment of sepsis
IL189077A0 (en) Novel use of peptide compounds for treating muscle pain
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease